These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35041852)

  • 1. Kinase inhibitor-induced cardiotoxicity assessed in vitro with human pluripotent stem cell derived cardiomyocytes.
    Xian HQ; Blanco C; Bonham K; Snodgrass HR
    Toxicol Appl Pharmacol; 2022 Feb; 437():115886. PubMed ID: 35041852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
    Rana P; Anson B; Engle S; Will Y
    Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4.
    Golforoush PA; Narasimhan P; Chaves-Guerrero PP; Lawrence E; Newton G; Yan R; Harding SE; Perrior T; Chapman KL; Schneider MD
    Sci Rep; 2020 Jul; 10(1):12060. PubMed ID: 32694738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
    Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
    Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
    Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
    Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
    Altrocchi C; Van Ammel K; Steemans M; Kreir M; Tekle F; Teisman A; Gallacher DJ; Lu HR
    Front Pharmacol; 2023; 14():1229960. PubMed ID: 37492082
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
    Sala L; Bellin M; Mummery CL
    Br J Pharmacol; 2017 Nov; 174(21):3749-3765. PubMed ID: 27641943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing flecainide block of I
    Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA
    Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling cadmium-induced cardiotoxicity using human pluripotent stem cell-derived cardiomyocytes.
    Shen J; Wang X; Zhou D; Li T; Tang L; Gong T; Su J; Liang P
    J Cell Mol Med; 2018 Sep; 22(9):4221-4235. PubMed ID: 29993192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
    Doherty KR; Wappel RL; Talbert DR; Trusk PB; Moran DM; Kramer JW; Brown AM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):245-55. PubMed ID: 23707608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment.
    Asahi Y; Nomura F; Abe Y; Doi M; Sakakura T; Takasuna K; Yasuda K
    Eur J Pharmacol; 2019 Jan; 842():221-230. PubMed ID: 30391349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
    Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
    J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promotion of maturation of human pluripotent stem cell-derived cardiomyocytes via treatment with the peroxisome proliferator-activated receptor alpha agonist Fenofibrate.
    Lee SG; Rhee J; Seok J; Kim J; Kim MW; Song GE; Park S; Jeong KS; Lee S; Lee YH; Jeong Y; Kim CY; Chung HM
    Stem Cells Transl Med; 2024 Aug; 13(8):750-762. PubMed ID: 38946019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.
    Maillet A; Tan KP; Brunham LR
    Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.